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Background and aims: Besides LDL-cholesterol, local vascular inﬂammation plays a key role in athero-
genesis. Efﬁcient therapies to treat the inﬂammatory component of the disease have not been estab-
lished. The discovery of specialized inﬂammation-resolving mediators, such as resolvins may provide
new opportunities for treatment. This study examines whether the u-3 fatty acid eicosapentaenoic acid-
derived resolvin E1 (RvE1), can reduce atherosclerosis, when administered alone or in combination with
a cholesterol-lowering statin.
Methods: ApoE*3Leiden mice were fed a hypercholesterolemic diet for 9 weeks and subsequently treated
with RvE1-low (1 mg/kg/day), RvE1-high (5 mg/kg/day), atorvastatin (1.5 mg/kg/day) or the combination
of atorvastatin and RvE1-low for the following 16 weeks.
Results: RvE1-low and RvE1-high reduced atherosclerotic lesion size to the same extent (35%; p < 0.05),
attenuated the formation of severe lesions, also seen as a proportional increase in the presence of mild
lesions, but did not alter plasma cholesterol levels. Cholesterol-lowering atorvastatin reduced athero-
sclerosis (27%, p < 0.05), and the combination of RvE1 and atorvastatin further attenuated lesion size
(51%, p < 0.01) and increased the content of mild lesions. RvE1 did not affect plasma SAA, E-selectin,
VCAM-1 or MCP-1 but did reduce plasma EPHX4 and down-regulated the local expression of pro-
atherogenic genes in the aortae, (e.g. Cd74, Cd44, Ccl2, Ccr5 and Adam17) and signiﬁcantly inactivated
IFN-g (p < 0.001) and TNF-a (p < 0.001) signalling pathways.
Conclusions: RvE1 attenuates atherogenesis both alone and on top of a statin. The local effects of RvE1
are demonstrated by the modulated aortic expression of genes involved in inﬂammatory and immune
responses, without altering plasma cholesterol or circulating SAA.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atherosclerotic plaque buildup is closely linked to an increased
exposure to low-density lipoprotein (LDL) cholesterol, which hasarch, Zernikedreef 9, 2333CK
Pharma Inc., 155 Brookline
gjorstrup@anidapharma.com
9 Hayden Avenue Lexington,
Ireland Ltd. This is an open accessbeen the rationale for treatment with LDL-lowering statins over the
last several decades. While the outcome of statin treatment un-
deniably is a reduction in cardiovascular disease (CVD) mortality,
this still remains a major cause of death worldwide [1]. However,
elevated LDL levels may be more important in the induction of
disease, while plaque progression and later potential rupture is
caused by vascular inﬂammation rather than high LDL levels per se.
Intimal retention of LDL and its subsequent modiﬁcation and
oxidation provide a chronic trigger of vascular inﬂammation. This
initially involves the innate immune system, with monocyte
recruitment and macrophage and dendritic cell activation, which
initiates later adaptive immune responses [2,3]. Due to thearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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ment, it is challenging to single out one pathway as a therapeutic
target, when considering an immune-based approach. Statins, in
addition to their LDL-lowering effects, have speciﬁc anti-
inﬂammatory properties in the vasculature [4] but may not offer
sufﬁcient control [5], nor have other attempts at treating athero-
sclerosis with anti-inﬂammatory drugs been successful [6]. A major
contributing factor to plaque build-up and instability is thought to
be compromised clearance mechanisms at the plaque level,
possibly suggesting a local imbalance between pro-inﬂammatory
events and counter-acting resolution mechanisms of the immune
system [7] suggesting that resolution may be dysfunctional.
The discovery of specialized pro-resolving mediators (SPMs)
may represent a therapeutic alternative to classic anti-
inﬂammatory drugs by harnessing the body’s own systems to
regulate inﬂammation and promote homeostasis, including acti-
vation of endogenous clearance mechanisms [8]. Originally iden-
tiﬁed as oxygenation products of omega-3 fatty acids in resolving
exudates of acute inﬂammation [9], these lipid-derived mediators
with agonistic properties, such as resolvins, protectins, and mar-
esins, are now established regulators of both acute and chronic
inﬂammatory responses [10]. In a dual action these mediators
dampen active pro-inﬂammatory pathways and concurrently acti-
vate pro-resolution functions such as phagocytic clearance and
tissue repair mechanisms. Uniquely, they appear to do so without
compromising host immune defense [10].
The ApoE*3Leiden transgenic mouse has a humanized lipopro-
tein proﬁle with elevated plasma cholesterol levels conﬁnedmainly
to the VLDL/LDL-sized lipoprotein fractions [11]. The model is well-
established to quantify the build-up of lesions and their potential
amelioration by drug intervention, and is well-characterized for
statins [12]. Using this model, we herein investigated the efﬁcacy of
resolvin E1 (RvE1), an endogenous SPM derived from eicosa-
pentaenoic acid, in attenuating atherosclerotic lesion development.
A putative anti-atherogenic effect of RvE1was studied at two doses,
and in combination with atorvastatin. A reference group was
treated with atorvastatin alone.
2. Materials and methods
2.1. Ethics statement
Experiments were approved by an independent Ethical Com-
mittee on Animal Care and Experimentation (Zeist, the
Netherlands; approval number DEC2680) and were performed in
compliance with the European Commission Directive on the use of
animals for scientiﬁc purposes.
2.2. Animals and treatments
Eighty female ApoE*3Leiden transgenic mice were fed an
atherogenic Western-type diet (HC) for a nine-week run-in period,
starting at 12e16 weeks of age. This diet contains 40.5% sucrose,
20% acid casein, 15% cocoa butter, 10% corn starch, 5.45% cellulose,
5.1% mineral mixture, 1% choline chloride, 1% corn oil, 0.2%
methionine and 0.4% cholesterol (all w/w) (AB-diets, Woerden, the
Netherlands). After the run-in period, in which plasma cholesterol
increased from 2.8 ± 0.4 mM to 17.5 ± 2.5 mM as expected for
ApoE*3Leiden transgenic mice, mice were divided into 5 treatment
groups that were matched for total plasma cholesterol (n ¼ 16/
group) continuing on HC with 1) vehicle control, 2) 1.5 mg/kg/day
atorvastatin, 3) 1 mg/kg/day RvE1 (RvE1-low), 4) 5 mg/kg/day RvE1
(RvE1-high), 5) or a combination of atorvastatin 1.5 mg/kg/day and
RvE11mg/kg/day (combination group), for the following 16 weeks.
Atorvastatin (Lipitor, Pﬁzer, Capelle a/d IJssel, the Netherlands) wassupplemented to the diet (0.0015% w/w), and RvE1 and vehicle
were administered daily by oral gavage between 9 and 10 a.m.
Resolvin E1 (RvE1; RX-10001) was provided by Resolvyx Pharma-
ceuticals Inc. (Cambridge, MA, USA). The dose RvE1 used in this
study was deﬁned based on previous experiments in humans and
mice. Brieﬂy, pharmacokinetic analysis of a single dose, 10 mg, 14C-
labeled RvE1 (approximately 0.15 mg/kg) in a Phase 1 clinical study
revealed a half-life of about 7 h (Resolvyx unpublished; trial
number NCT00941018). Furthermore, administration of repeated
doses of 100 mg and higher in the same study were well-tolerated
and without safety-related issues. In mice, 14C-labeled RvE1 at
1 mg/kg resulted in plasma concentrations greater than 3 nM,
which is the EC50 deﬁned in in vitro experiments. These levels
(>3 nM) were maintained for a period of 8 h post-administration.
(Resolvyx unpublished).
All animals had free access to water and food. Body weight and
food intake were monitored throughout the study. Animals were
sacriﬁced by CO2 asphyxiation after 16 weeks of treatment (at
37e41 weeks of age) to collect hearts including the aortic roots
which were ﬁxed in formalin and embedded in parafﬁn for
atherosclerosis analysis.
Prior to the main study described above, a pilot experiment was
performed using the same experimental conditions but with 9
weeks of RvE1 intervention. This experiment served to investigate
whether a dose of 1mg/kg is efﬁcacious in a setting of experimental
diet-induced atherosclerosis and to establish a microarray gene
expression dataset of aortae.
2.3. Biochemical, histological and microarray gene expression
analyses
A detailed description of biochemical, histological and aortic
microarray analyses is provided in Supplemental methods. In brief,
plasma parameters (total cholesterol, serum amyloid A, E-selectin
and alanine aminotransferase) were quantiﬁed using commercially
available assays as described previously [13,14]. Atherosclerosis
was scored blindly in 4 serial cross-sections (at 50 mm intervals) of
the aortic root. Morphometric analysis of lesion number and area
was performed using cell^ D software (version 2.7; Olympus Soft
Imaging Solutions, Hamburg, Germany), and lesion severity was
scored according to the established classiﬁcation of the American
Heart Association [15,16]. Aortic genome-wide gene expression
analyses were performed using Illumina microarray analysis fol-
lowed by established normalisation and quality control protocols
and pathway analysis as described [17,18].
2.4. Statistical analysis
Signiﬁcance of differences was tested using one-way ANOVA
with LSD post-hoc test. Statistical tests were performed using SPSS
software (version 20, IBM, Armonk USA). A p-value <0.05 was
considered statistically signiﬁcant. All data are presented as
mean ± SEM.
3. Results
3.1. RvE1 treatment reduces atherosclerotic lesion area
ApoE*3Leiden transgenic mice were fed the HC diet for 9 weeks
to induce atherosclerotic lesions, after which treatment with RvE1
was started and continued for another 16weeks until the end of the
study. Analysis of atherosclerotic lesions in the valve area of the
aortic root (Fig. 1AeE) revealed a clear treatment effect of RvE1
relative to vehicle in which the total lesion area was
163,200 ± 17,410 mm2. Both RvE1-low (105,300 ± 12,200 mm2) and
Fig. 1. Treatment with RvE1 reduces atherosclerotic lesion area. (A) Representative images of haematoxylin-phloxine-saffron stained cross-sections of the aortic root after 16
weeks of treatment with vehicle, (B) RvE1-low 1 mg/kg/day, (C) RvE1-high 5 mg/kg/day, (D) atorvastatin 1.5 mg/kg/day, (E) combination of atorvastatin 1.5 mg/kg/day and RvE1
1 mg/kg/day. (F)Quantiﬁcation of total atherosclerotic lesion area in serial cross-sections of the aortic root after 16 weeks of treatment. Results are shown as mean ± SEM
(n ¼ 15e16/group). *p < 0.05, **p < 0.01 vs. the vehicle group.
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area by around 35% compared with vehicle control (both p < 0.05
vs. vehicle) (Fig. 1F). The reference compound atorvastatin
(119,400 ± 16,410 mm2) reduced atherosclerosis to a comparable
extent as RvE1 (27% reduction; p < 0.05 vs. vehicle). Notably, the
combination treatment had the strongest effect on atherosclerosis
(82,300 ± 1522 mm2) equaling a 51% reduction (p < 0.001 vs.
vehicle). The lesion area of this group tended to be 31% smaller than
with atorvastatin (p ¼ 0.11 vs. atorvastatin).
In ApoE*3Leiden transgenic mice, the reduction in lesion area
upon statin treatment is closely linked to the cholesterol-lowering
effects of these drugs [11,12]. In the current study, atorvastatin
reduced plasma cholesterol levels from 17.5 ± 0.3 mM before the
start of treatment to 12.0 ± 0.4 mM at endpoint (18% reduction vs.
vehicle; p < 0.001) (Fig. 2A). RvE1 had no effect on plasma
cholesterol levels at either dose, nor did RvE1 affect the lipoprotein
proﬁle or HDL cholesterol levels (data not shown). Combined
treatment with RvE1 and atorvastatin reduced cholesterol levels tothe same degree as atorvastatin alone (18% reduction at endpoint;
p < 0.01 vs. vehicle) (Fig. 2A). Atorvastatin and the combination
treatment reduced the total cholesterol exposure, calculated over
the entire treatment period, by 21% and 17% (both p < 0.001 vs.
vehicle) respectively (Fig. 2B), while cholesterol exposure was not
affected by RvE1.3.2. RvE1 treatment improves lesion severity
To further elucidate how RvE1 interferes with the progression of
atherosclerosis, aortic segments were analyzed for presence or
absence of lesions and the number of lesion-free segments was
determined (Fig. 3A). When lesions were present, each individual
lesion was graded to determine its severity according to the clas-
siﬁcation system developed by the American Heart Association
[15,16] (Fig. 3B).
In the vehicle group, 8 ± 3% of all aortic segments were free of
lesions (Fig. 3A). A higher content of lesion-free segments was
Fig. 2. Treatment with RvE1 does not reduce plasma cholesterol. (A) Plasma
cholesterol levels over time in the different treatment groups from t ¼ 0 to t ¼ 25
weeks. (B) Cholesterol exposure during the 16-weeks treatment period. Results are
shown as mean ± SEM (n ¼ 15e16/group). *p < 0.05, **p < 0.01, ***p < 0.001 vs. the
vehicle group.
Fig. 3. RvE1 treatment increases proportion of lesion-free segments and incidence
of mild lesions. (A) Percentage of lesion-free segments in the aortic root. (B) Lesion
severity as a percentage of all lesions, ranging from type I (mild) to type V (severe)
lesions, after 16 weeks of treatment. Results are shown as mean ± SEM (n ¼ 15e16/
group). *p < 0.05 and **p < 0.01 vs. the vehicle group. $p < 0.05 vs. the atorvastatin
group.
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atorvastatin (11 ± 4%) but these effects were not signiﬁcant. The
combination treatment had the highest content of lesion-free
segments (18 ± 4%, p ¼ 0.07 vs. vehicle).
A more reﬁned analysis of lesion severity showed that all
experimental groups exhibited lesions ranging from mild (I) to
most severe (V) (Fig. 3B). However, there was a striking difference
in distribution of severity scores in favor of milder lesions in the
RvE1-treated groups. Most notably the content of mild type I le-
sions (early fatty streaks) was almost doubled in the low-dose RvE1
group, with 22 ± 5% type I lesions, compared to 12 ± 2% in the
vehicle group (p ¼ 0.17, Fig. 3B). The effect of RvE1 seemed to be
dose-dependent as this percentage was further increased to
32 ± 7% in the high-dose group (p < 0.01 vs. vehicle). Although
reference atorvastatin alone did not affect the content of type I
lesions (14 ± 4%, n.s. vs. vehicle), the combination treatment
resulted in signiﬁcantly more of these mild lesions (34 ± 7%,
combination vs. vehicle p < 0.01, combination vs. atorvastatin
p < 0.05, Fig. 3B) indicating that the observed attenuation of lesion
severity can be ascribed to RvE1.
In the vehicle control group 31 ± 6% of the lesions were severe
type V lesions. RvE1-treated groups contained less type V lesions
(RvE1-low 18 ± 3%, n.s. vs. vehicle and RvE1-high 16 ± 4%, p < 0.05
vs. vehicle) which represents a reduction of 42% and 48%, respec-
tively (Fig. 3B). The content of type V lesions was also reduced byatorvastatin (15 ± 4%, p < 0.01 vs. vehicle), and the combination
treatment had the lowest content of type V lesions (10 ± 3%,
p < 0.01 vs. vehicle) equaling a reduction of 67%.
3.3. Effect of RvE1 treatment on the composition of aortic lesions
To investigate whether RvE1 treatment may affect the compo-
sition of aortic lesions, we analyzed the collagen area, the macro-
phage area, the vascular smooth muscle cell (VSMC) of the lesions.
Data are shown as percentages of the plaque area (Fig. 4).
PicroSirius Red staining showed that the lesional collagen area
was 45 ± 3% in the vehicle control group (Fig. 4). This was not
affected by RvE1 treatment (48 ± 3% in RvE1-low, 49 ± 1% in RvE1-
high). Atorvastatin treatment increased the collagen content
(61 ± 2%, p < 0.01 vs. vehicle), an effect that was not observed in the
combination treatment (50 ± 3%).
The percentage of VSMC area (Fig. 4), as assessed by immuno-
histochemical staining for alpha smoothmuscle actin, was 6 ± 1% in
vehicle control animals. RvE1-low treatment increased the VSMC
content (11 ± 1%, p < 0.05). Neither RvE1-high (8 ± 1%) nor ator-
vastatin treatment (7 ± 1%) nor the combination treatment (9 ± 1%)
had a signiﬁcant effect on the VSMC area of aortic lesions.
Immunohistochemical staining showed that MAC-3-positive
cells (macrophages; Fig. 4) were present in aortic lesions of the
vehicle control group (MAC-3-positive area 13 ± 2%). RvE1 treat-
ment (RvE1-low dose 15 ± 1%; RvE1-high dose 18 ± 2%) and ator-
vastatin (11 ± 2%) did not affect this area. The MAC-3 positive area
was increased in the combination group (20 ± 3%; p < 0.05) when
Fig. 4. Effect of RvE1 treatment on the composition of aortic lesions. Percentages of
collagen area (Picrosirius red staining), macrophage area (immunohistochemical
staining of MAC-3) and vascular smooth muscle cell area (immunohistochemical
staining of alpha smooth muscle actin) of atherosclerotic lesions after 16 weeks of
treatment. The remaining lesional area (referred to as ‘other’) consists of e.g. necrotic
core with cholesterol clefts and proteoglycans. Results are shown as mean ± SEM
(n ¼ 13e15/group). *p < 0.05 and **p < 0.01 vs. vehicle. $p < 0.05 vs. atorvastatin.
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The remainder of the lesion area consisting of necrotic core with
cholesterol clefts and proteoglycans was 35 ± 4% in vehicle control
animals (Fig. 4). RvE1 treatment signiﬁcantly decreased the per-
centage of this area (27 ± 3% in RvE1-low and 24 ± 2% in RvE1-high,
both p < 0.05). A signiﬁcant decrease was also observed for ator-
vastatin treatment (21 ± 2%, p < 0.01) and the combination treat-
ment (21 ± 4%, p < 0.01).
Targeted analysis of gene expression levels of chemokines and
cell surface receptors commonly associated with pro-inﬂammatory
macrophages (Cxcl10, Cxcl11, Ccr7) as well as receptors associated
with macrophages contributing to resolution (Cd163,Mrc1) did not
reveal an effect of RvE1 treatment (RT-PCR analysis; not shown).
Atorvastatin did also not cause any change in the expression of
these receptors.
3.4. Effects of RvE1 on circulating markers of inﬂammation
To further characterize the anti-atherogenic effect of RvE1, we
measured circulating markers of inﬂammation that are involved in
atherogenesis. Serum amyloid A (SAA) is a liver-derived inﬂam-
mation marker that can exert pro-atherogenic effects in the
vasculature [19]. E-selectin and VCAM-1 are expressed on activated
endothelial cells and involved in immune cell adhesion and
recruitment [20]. In addition, we measured circulating levels of
Monocyte Chemoattractant Protein-1 (MCP-1), a chemokine that is
reported to play an important role in the pathogenesis of athero-
sclerosis [21]. SAA levels rose in the vehicle group from 4.7 ± 0.3 mg/
ml at the beginning of the study (data not shown) to 6.2 ± 0.7 mg/ml
at the end of the study. SAA levels were not affected by RvE1-low
(6.4 ± 0.5 mg/ml), RvE1-high (6.9 ± 0.4 mg/ml), atorvastatin
(5.4 ± 0.3 mg/ml), or the combination treatment (5.9 ± 0.6 mg/ml)
(Table 1). E-selectin also increased over time in the vehicle control
group, from 51.8 ± 1.4 ng/ml at the start of the study (not shown) to
68.1 ± 2.8 ng/ml at the end of the study. E-selectin levels were not
affected by RvE1-low (65.7± 3.0 ng/ml) or RvE1-high (67.5 ± 1.5 ng/
ml) (Table 1). Atorvastatin signiﬁcantly reduced E-selectin
(53.2 ± 1.7 ng/ml; p < 0.001 vs. vehicle), an effect that was not
further enhanced by combination with RvE1 (51.1 ± 2.4 ng/ml;
p < 0.001 vs. vehicle) (Table 1). Similarly, VCAM-1 levels increased
over time in the vehicle control group from 2.20 ± 0.05 mg/ml at the
start of the study (not shown), to 3.56 ± 0.22 mg/ml at the end of the
study (Table 1). Comparable to the effects observed for E-selectin,VCAM-1 levels were not affected by RvE1-low (3.25 ± 0.09 mg/ml)
or RvE1-high (3.23 ± 0.13 mg/ml) while they were similarly reduced
relative to vehicle control in atorvastatin-treated and combination-
treated animals (2.68 ± 0.20 mg/ml and 2.79 ± 0.08 mg/ml respec-
tively; both p < 0.001 vs. vehicle; Table 1). Circulating levels of the
chemokine MCP-1 were not affected by RvE1 at either dose, nor
were they affected by atorvastatin or the combination treatment of
atorvastatin and RvE1 (Table 1). Sincewe observed no effect of RvE1
treatment on these conventional circulating markers of inﬂam-
mation, we questioned whether it may affect a different type of
inﬂammatory marker, namely epoxide hydrolase 4 (EPHX4), which
is considered to be pro-atherogenic through its role in the degra-
dation of the anti-inﬂammatory and atheroprotective epox-
yeicosatrienoic acids (EETs) [22,23]. Plasma EPHX4 levels were
30.9 ± 2.0 ng/ml in the vehicle control group at the end of the study
(Table 1). Both RvE1-low and RvE1-high signiﬁcantly reduced
plasma EPHX4 (25.8 ± 1.7 ng/ml, p < 0.05 vs. vehicle in RvE1 low;
23.5 ± 1.5 ng/ml, p < 0.01 vs. vehicle in RvE1 high). Atorvastatin
treatment also reduced circulating EPHX4 (23.5 ± 1.2 ng/ml,
p < 0.01 vs. vehicle), and the strongest reduction was observed in
the combination-treated animals (20.7 ± 1.1 ng/ml, p < 0.001 vs.
vehicle) (Table 1).
Alanine aminotransferase (ALAT), a liver integrity marker,
increased during atherogenic diet feeding from 53.3 ± 2.1 U/L at
baseline, to 139.4 ± 24.8 U/L at the end of the study in the vehicle
control group. Treatment with RvE1 did not affect ALAT levels
(RvE1-low 116.3 ± 13.2; RvE1-high 108.6 ± 24.4) (Table 1). Plasma
ALAT levels were signiﬁcantly lower in atorvastatin treated animals
(76.5 ± 12.6 U/L; p < 0.05 vs. vehicle) and the combination treat-
ment also resulted in attenuated ALAT levels (67.5 ± 12.5 U/L,
p < 0.05 vs. vehicle, n.s. vs. atorvastatin) which were comparable to
the atorvastatin group (Table 1).
3.5. RvE1 down-regulates inﬂammatory genes and pathways in the
vasculature
To evaluate potential early gene expression changes in aorta,
aortae collected from ApoE*3Leiden mice treated with RvE1 (1 mg/
kg) or vehicle for a period of 9 weeks were used for a compre-
hensive gene expression analysis by microarray. RvE1 signiﬁcantly
affected the expression of 73 genes involved in the biological pro-
cess “Inﬂammation” (see Supplementary Table S1) and 62 genes in
“Immune cell trafﬁcking” (see Supplementary Table S2). Among the
genes down-regulated with RvE1 several are known to be involved
in atherogenesis, e.g. Ctss, Cd74, Cd44, Hpse, Ifr5, Ccl2, Csp1, Il20rb,
Ccr5 and Adam17. Also, genes involved in antigen presentation and
dendritic cell maturation, including Lilrb3, Lair1, Casp1, Ctss, Irf5,
Lat2, Tyrobp, Hla-dqb1, Hla-Dma, Cd74, Hla-Drb5 were down-
regulated by RvE1. Subsequent pathway analysis revealed a sig-
niﬁcant inactivation of the pathways downstream of IFN-g (Z-score
4.05; p < 0.001) and TNF-a (Z-score 3.10; p < 0.001) in aortae of
RvE1-treated mice. These results indicate pro-resolution of
inﬂammation by RvE1 in atherogenesis.
4. Discussion
Herein we report that intervention with RvE1, an endogenous
oxidation product of the u-3 PUFA eicosapentaenoic acid (EPA)
with inﬂammation resolution properties [26], attenuated athero-
sclerotic lesion development when administered orally once daily
over a period of 16 weeks in mice with established progressive
atherosclerosis. RvE1 reduced total lesion area by 35%, and in ani-
mals treated with RvE1 the proportion of atherosclerotic lesions
was signiﬁcantly skewed towards mild (type I) lesions over more
severe (type IV and V) lesions. RvE1 had no effect on plasma
Table 1
Plasma parameters at the end of the study (t ¼ 25 weeks).
Vehicle RvE1-low RvE1-high Atorva Combi
SAA (mg/ml) 6.2 ± 0.7 6.4 ± 0.5 6.9 ± 0.4 5.4 ± 0.3 5.9 ± 0.6
E-selectin (ng/ml) 68.1 ± 2.8 65.7 ± 3.0 67.5 ± 1.5 53.2 ± 1.7*** 51.1 ± 2.4***
VCAM-1 (mg/ml) 3.56 ± 0.22 3.25 ± 0.09 3.23 ± 0.13 2.68 ± 0.20*** 2.79 ± 0.08***
MCP-1 (pg/ml) 42.4 ± 3.8 40.7 ± 3.3 46.1 ± 5.8 33.5 ± 2.8 42.3 ± 5.5
EPHX4 (ng/ml) 30.9 ± 2.0 25.8 ± 1.7* 23.5 ± 1.5** 23.5 ± 1.2** 20.7 ± 1.1***
ALAT (U/l) 139.4 ± 24.8 116.3 ± 13.2 108.6 ± 24.4 76.5 ± 12.6* 67.5 ± 12.5*
Results are shown as mean ± SEM (n ¼ 12e16/group). *p < 0.05, **p < 0.01, ***p < 0.001 vs. the vehicle group.
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active comparator used. Atorvastatin attenuated atherosclerosis by
27% and reduced plasma cholesterol concentrations by 18%, but had
no effect on lesion distribution towards milder lesions. Combina-
tion treatment with RvE1 and atorvastatin caused a more pro-
nounced reduction of atherosclerotic lesion area (by 51%) with
retained reduction in lesion severity, as observed with RvE1 alone.
Gene expression analysis of aortae showed that RvE1 reduced
activation of speciﬁc inﬂammatory pathways (IFN-g and TNF-a) and
diminished the expression of speciﬁc pro-atherogenic inﬂamma-
tory factors.
In the current study we used atorvastatin as reference com-
pound. The hypolipidemic effects of statins, among which ator-
vastatin, in the ApoE*3Leiden transgenic mouse model have been
described in many studies ([11,12] and references therein). The
anti-atherosclerotic activities of statins in ApoE*3Leiden transgenic
mice are strongly related to their (V)LDL cholesterol-lowering ef-
fects [11], and high statin doses are needed to substantially quench
inﬂammation [24,27,28]. The dose of atorvastatin employed in the
present study was low (1.5 mg/kg/day) and plasma cholesterol was
lowered by 18%. This hypolipidemic effect is in a clinically relevant
range, i.e. as also observed in atorvastatin-treated patients ([12]
and references therein). Under the experimental conditions
employed, atorvastatin reduced atherosclerosis by 27%. Notably,
the efﬁcacy of RvE1 monotherapy to attenuate atherosclerotic
lesion development was evenmore pronounced. Importantly, RvE1
signiﬁcantly reduced lesion load and improved lesion severity in
absence of an effect on plasma cholesterol which remained unal-
tered and high (~16 mM). RvE1 increased the content of mild type I
lesions, an effect that was not observed in the case of atorvastatin.
Furthermore, the content of severe type V lesions was decreased by
RvE1. The composition of these severe lesions is considered tomake
them unstable and prone to rupture. Therefore, the observed shift
towards a higher proportion of mild lesions and lower proportion
of severe lesion in the RvE1 treated animals could indicate a
beneﬁcial effect of RvE1 on risk of plaque rupture. Defective
immune-cell-mediated clearance in atherosclerotic lesions has
been suggested as a major component in progressive disease, and is
not restored by statin treatment [7]. In this respect, and in marked
contrast to atorvastatin, RvE1 did not reduce the macrophage
content in lesions. This is consistent with observations in vivowith
another SPM, neuroprotectin D1, where resolution of
inﬂammation-driven retinal neovascularization in a model of wet
age-related macular degeneration (AMD) occurred in the absence
of change in numbers of microglia but with clear conversion to a
pro-resolution ramiﬁed shape [29]. The reduction in necrotic core
in the atherosclerotic lesions of RvE1 treated animals may point to
enhanced macrophage phagocytosis as previously reported [37].
We investigated a potential change in the gene expression of
macrophage cell surface receptors that would allow differentiation
between different subsets of macrophages, but we could not detect
any difference between control or RvE1-treated animals. Impor-
tantly, many of the processes thought to be resolved by SPMs arenatural endogenous processes with a relatively short occurrence (a
fewweeks) during the entire process of atherogenesis (>20weeks).
For instance, the process of neutrophil inﬁltration into the vascu-
lature takes place at around 10 weeks of atherogenic diet-feeding
and lasts only for a few weeks, i.e. it cannot be studied at later
time points [13,30]. Thus, it is likely that any histological analysis of
immune cells in aortic lesions at endpoint does not allow identiﬁ-
cation of the inﬂammatory event during atherogenesis that was
resolved by RvE1.
Furthermore, it is also increasingly recognized that macrophage
cell surface molecule expressionmay not fully reﬂect the functional
stage of a macrophage [31], and for technical reasons we were
limited to a few markers. Thus, it is unlikely that immunohisto-
chemical analysis of putative macrophage cell surface markers in
aortic lesions at a 25-week endpoint would allow us to identify in
full or even partially the macrophage effector proﬁle contributing
to lesion reduction in the presence of RvE1.
The observed reduction in EPHX4 by RvE1 may potentially
contribute to inﬂammation resolution because low levels of EPHX4
may lead to increases in epoxyeicosatrienoic acids with known
resolution properties [22,23]. Furthermore, inhibitors of EPHX4
have been shown to attenuate experimental atherosclerosis in
ApoE/ mice [40].
Microarray analysis of gene expression changes in aortae
collected earlier in time (at 18 weeks of the study) revealed that
RvE1-treated animals displayed reduced expression of genes
related to inﬂammation and immune cell trafﬁcking compared
with the untreated controls. For instance, RvE1 down-regulated the
expression of chemokines or chemokine receptors (e.g. Ccl2, Ccr5)
suggesting a dampening effect on immune cell trafﬁcking and
innate immunity. Furthermore, RvE1 reduced the expression of
MHC class II molecules suggesting a role for RvE1 in regulation of T-
cell responses in atherosclerosis by reducing antigen presentation.
Consistent with this, RvE1 was shown to regulate expression of co-
stimulatorymolecules CD-80 and CD-86 [32], and also dampen TH1
and TH17 T-cell responses, while upregulating IL-10 to promote
corneal clearance in herpes simplex virus-induced ocular keratitis
[33]. Novel ﬁndings in the present study were that several genes,
whose products are known to be involved in atherogenesis, were
beneﬁcially affected by RvE1, including Cd74, Casp1, and Cd44. An
integrated analysis of gene expression patterns across pathways
showed that RvE1 signiﬁcantly reduced activation of the inﬂam-
matory signaling routes triggered by TNF-a and IFN-g, both of
which are known to control crucial pro-atherogenic pathways
during lesion development [34,35]. The observed effects of RvE1 in
downregulating pro-inﬂammatory mediators is concordant with
previous studies on RvE1 that described attenuated secretion of
pro-inﬂammatory cytokines, including IFN-g, IL-6, IL-1b and TNF-a,
and the attenuation of neutrophil and macrophage inﬁltration at
sites of inﬂammation [36,37]. Consistent with this and our ﬁndings,
topical gingival treatment of periodontitis with RvE1 also reduced
atherosclerosis in a rabbit model of disease, which was accompa-
nied by a dampening effect on inﬂammation [38].
K. Salic et al. / Atherosclerosis 250 (2016) 158e165164In the present study we studied for the ﬁrst time the efﬁcacy of
resolvin E1 in a diet-inducible model of atherosclerosis. While we
demonstrate the principle of atherosclerosis treatment with
resolvin E1, the study was not designed to study or unravel the
underlying mechanisms such as phenotypic changes of inﬂamma-
tory cells. Future studies should include a reﬁned characterization
of circulating as well as tissue-resident inﬂammatory cells to pro-
vide insight into the mechanisms underlying these effects.
In the current study, en face Oil Red O lipid staining of the aorta,
which is a commonly used method for quantiﬁcation of athero-
sclerosis extension, was not performed. The method employed
herein is an established method for analysis of atherosclerosis
[11,13,24,25] that not only allows quantiﬁcation of lesion load (with
results comparable to those obtained from en face staining [25,39]),
but also provides information on the severity of atherosclerotic
lesions.
Taken together, our results demonstrate for the ﬁrst time the
efﬁcacy of an SPM, RvE1, in an experimental model of diet-induced
atherosclerosis, the ApoE*3Leiden transgenic mouse, and further
support the concept that defective resolution of inﬂammation may
contribute to progression of atherosclerotic disease. While RvE1
showed comparable efﬁcacy to that of an established statin in
attenuating atherosclerosis, the more pronounced effect of their
combined actions is indicative of a therapeutic potential of SPM in
atherosclerosis, and the added beneﬁt of activating pro-resolution
pathways on top of existing ﬁrst line treatment.
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